AIMS/HYPOTHESIS: Improvements in islet transplantation require clinical series large enough to implement controlled new strategies. The goal of this study was to demonstrate the feasibility of a multicentre network for islet transplantation in Type I (insulin-dependent) diabetic patients. METHODS: The five centres (Besançon, Geneva, Grenoble, Lyon, Strasbourg) of the GRAGIL network allow pancreas procurement, recipient recruitment, transplantation procedure and follow-up. Islet isolation is, however, performed in one single laboratory (Geneva). Pancreata were procured in each of the five centres and transported to Geneva with an ischaemia time of less than 8 hours. Islets were isolated using a standard automated method. If the islet number was too low for a graft (< 6,000 Islet-equivalent/kg), islets were cultured up to 12 days until another isolation was possible. Islets were transplanted by percutaneous transhepatic intraportal injection. Immunosuppression consisted of cyclosporine, mycophenolate mofetil, steroids and an anti-interleukin 2 receptor antibody. RESULTS: From March 1999 to June 2000, 56 pancreata procurements were performed with an average yield of 234500 islet-equivalent, with 32 preparations over 200000 islet-equivalent. Ten C-peptide negative Type I diabetic patients (5 men and 5 women, median age 44 years, median diabetes duration 29 years) with an established kidney graft (> 6 months) received 9,030 +/- 1,090 islet-equivalent/kg with a median purity of 63 %. The number of pancreata required for each graft was 1 (n = 5) or 2 (n = 5). At the completion of a 12 month follow-up, we observed 0% primary nonfunction, 50% graft survival and 20% insulin-independence. CONCLUSIONS/ INTERPRETATION: This study demonstrates the interest and the feasibility of a multicentre collaboration in human islet transplantation.
AIMS/HYPOTHESIS: Improvements in islet transplantation require clinical series large enough to implement controlled new strategies. The goal of this study was to demonstrate the feasibility of a multicentre network for islet transplantation in Type I (insulin-dependent) diabeticpatients. METHODS: The five centres (Besançon, Geneva, Grenoble, Lyon, Strasbourg) of the GRAGIL network allow pancreas procurement, recipient recruitment, transplantation procedure and follow-up. Islet isolation is, however, performed in one single laboratory (Geneva). Pancreata were procured in each of the five centres and transported to Geneva with an ischaemia time of less than 8 hours. Islets were isolated using a standard automated method. If the islet number was too low for a graft (< 6,000 Islet-equivalent/kg), islets were cultured up to 12 days until another isolation was possible. Islets were transplanted by percutaneous transhepatic intraportal injection. Immunosuppression consisted of cyclosporine, mycophenolate mofetil, steroids and an anti-interleukin 2 receptor antibody. RESULTS: From March 1999 to June 2000, 56 pancreata procurements were performed with an average yield of 234500 islet-equivalent, with 32 preparations over 200000 islet-equivalent. Ten C-peptide negative Type I diabeticpatients (5 men and 5 women, median age 44 years, median diabetes duration 29 years) with an established kidney graft (> 6 months) received 9,030 +/- 1,090 islet-equivalent/kg with a median purity of 63 %. The number of pancreata required for each graft was 1 (n = 5) or 2 (n = 5). At the completion of a 12 month follow-up, we observed 0% primary nonfunction, 50% graft survival and 20% insulin-independence. CONCLUSIONS/ INTERPRETATION: This study demonstrates the interest and the feasibility of a multicentre collaboration in human islet transplantation.
Authors: A N Balamurugan; Gopalakrishnan Loganathan; Melena D Bellin; Joshua J Wilhelm; James Harmon; Takayuki Anazawa; Sajjad M Soltani; David M Radosevich; Takeshi Yuasa; Mukesh Tiwari; Klearchos K Papas; Robert McCarthy; David E R Sutherland; Bernhard J Hering Journal: Transplantation Date: 2012-04-15 Impact factor: 4.939
Authors: John S Kaddis; Matthew S Hanson; James Cravens; Dajun Qian; Barbara Olack; Martha Antler; Klearchos K Papas; Itzia Iglesias; Barbara Barbaro; Luis Fernandez; Alvin C Powers; Joyce C Niland Journal: Cell Transplant Date: 2012-08-10 Impact factor: 4.064
Authors: D M Berman; J J O'Neil; L C K Coffey; P C J Chaffanjon; N M Kenyon; P Ruiz; A Pileggi; C Ricordi; Norma S Kenyon Journal: Am J Transplant Date: 2009-01 Impact factor: 8.086
Authors: Ali Aldibbiat; Guo Cai Huang; Min Zhao; Graham N Holliman; Linda Ferguson; Stephen Hughes; Ken Brigham; Julie Wardle; Rob Williams; Anne Dickinson; Steven A White; Paul R V Johnson; Derek Manas; Stephanie A Amiel; James A M Shaw Journal: Cell Med Date: 2011-12-09